Traders Sell Pfizer Inc. (PFE) on Strength (PFE)
Traders sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Wednesday. $58.93 million flowed into the stock on the tick-up and $127.80 million flowed out of the stock on the tick-down, for a money net flow of $68.87 million out of the stock. Of all companies tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.02 for the day and closed at $36.85
A number of research firms have recently commented on PFE. BMO Capital Markets restated a “buy” rating on shares of Pfizer in a report on Thursday, April 28th. Sanford C. Bernstein set a $36.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, May 3rd. Independent Research GmbH set a $37.00 price target on Pfizer and gave the company a “neutral” rating in a report on Wednesday, May 4th. Goldman Sachs Group Inc. reiterated a “neutral” rating and issued a $35.00 price target on shares of Pfizer in a report on Monday, April 18th. Finally, S&P Equity Research reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, April 12th. Ten equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $38.19.
The company’s 50 day moving average is $35.58 and its 200 day moving average is $32.51. The stock has a market cap of $223.49 billion and a P/E ratio of 30.20.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.55 by $0.12. The firm earned $13 billion during the quarter, compared to the consensus estimate of $12 billion. The business’s revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.51 EPS. Equities research analysts forecast that Pfizer Inc. will post $2.45 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Friday, August 5th will be issued a dividend of $0.30 per share. The ex-dividend date is Wednesday, August 3rd. This represents a $1.20 annualized dividend and a dividend yield of 3.26%.
In other news, VP Loretta V. Cangialosi sold 86,000 shares of the business’s stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $33.97, for a total transaction of $2,921,420.00. Following the transaction, the vice president now owns 271,663 shares in the company, valued at approximately $9,228,392.11. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Anthony J. Maddaluna sold 8,950 shares of the business’s stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $33.75, for a total transaction of $302,062.50. Following the transaction, the executive vice president now owns 88,922 shares in the company, valued at approximately $3,001,117.50. The disclosure for this sale can be found here.
Other hedge funds and institutional investors recently bought and sold shares of the company. Simmons First Trust Co. NA increased its position in Pfizer by 50.4% in the fourth quarter. Simmons First Trust Co. NA now owns 152,716 shares of the biopharmaceutical company’s stock valued at $4,929,000 after buying an additional 51,146 shares during the last quarter. Korea Investment CORP increased its position in Pfizer by 12.6% in the fourth quarter. Korea Investment CORP now owns 4,474,881 shares of the biopharmaceutical company’s stock valued at $144,449,000 after buying an additional 499,200 shares during the last quarter. First Merchants Corp increased its position in Pfizer by 8.2% in the fourth quarter. First Merchants Corp now owns 46,918 shares of the biopharmaceutical company’s stock valued at $1,514,000 after buying an additional 3,572 shares during the last quarter. World Asset Management Inc increased its position in Pfizer by 4.7% in the fourth quarter. World Asset Management Inc now owns 643,965 shares of the biopharmaceutical company’s stock valued at $20,787,000 after buying an additional 29,078 shares during the last quarter. Finally, Fort Pitt Capital Group LLC bought a new position in Pfizer during the fourth quarter valued at about $6,324,000.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.